Supriya Lifescience share slipped 5.65 per cent at Rs 661.20 a piece on the BSE in Monday's intraday trade despite the pharma company reporting strong quarterly earnings for the financial year 2024-25
Supriya Lifescience Chairman and Whole-Time Director Satish Wagh said he was confident of achieving 22 per cent year-on-year revenue growth in the current financial year (FY25)
Supriya Lifesciences share price surged after the company inaugurated a new active pharmaceutical ingredients (APIs) production block, Module E, at the Lote Parshuram site in Maharashtra